Literature DB >> 10556217

TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.

L Hernández1, M Pinyol, S Hernández, S Beà, K Pulford, A Rosenwald, L Lamant, B Falini, G Ott, D Y Mason, G Delsol, E Campo.   

Abstract

Anaplastic large cell lymphoma (ALCL) is associated with the t(2;5)(p23;q35), which generates the NPM-ALK fusion gene encoding an 80-kD protein. Several studies have suggested that genes other than NPM may be fused to the ALK gene. Here we have identified TRK-fused gene (TFG) as a new ALK partner in 2 ALCL, 1 of which exhibited a t(2;3)(p23;q21). In these cases, TFG was involved in 2 different fusion genes, TFG-ALK(S) and TFG-ALK(L), coding respectively 85-kD and 97-kD chimeric proteins. The ALK breakpoint in these translocations was the same as in the classic t(2;5) translocation. These 2 proteins were both active in an in vitro tyrosine kinase assay showing that the new cloned cDNA sequences are translated into chimeric proteins with functional activity. These findings indicate that TFG can provide an alternative to NPM as a fusion partner responsible for activation of the ALK and the pathogenesis of ALCL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556217

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.

Authors:  B Maes; V Vanhentenrijk; I Wlodarska; J Cools; B Peeters; P Marynen; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

3.  5'-(RACE) identification of rare ALK fusion partner in anaplastic large cell lymphoma.

Authors:  N Scott Reading; Stephen D Jenson; Jeffrey K Smith; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

4.  The PB1 domain and the PC motif-containing region are structurally similar protein binding modules.

Authors:  Sosuke Yoshinaga; Motoyuki Kohjima; Kenji Ogura; Masashi Yokochi; Ryu Takeya; Takashi Ito; Hideki Sumimoto; Fuyuhiko Inagaki
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

5.  A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer.

Authors:  Mikael Herlevsen; Gary Oxford; Celeste Ptak; Jeffrey Shabanowitz; Donald F Hunt; Mark Conaway; Dan Theodorescu
Journal:  Biochem Biophys Res Commun       Date:  2006-11-21       Impact factor: 3.575

Review 6.  Regulation of traffic and organelle architecture of the ER-Golgi interface by signal transduction.

Authors:  Kerstin D Tillmann; Valentina Millarte; Hesso Farhan
Journal:  Histochem Cell Biol       Date:  2013-07-03       Impact factor: 4.304

7.  Transforming ER exit: protein secretion meets oncogenesis.

Authors:  Silvere Pagant; Elizabeth Miller
Journal:  Nat Cell Biol       Date:  2011-05       Impact factor: 28.824

Review 8.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

Review 9.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.